CeriBell (NASDAQ:CBLL) Director Sells $101,255.00 in Stock

CeriBell, Inc. (NASDAQ:CBLL) Director Joseph Michael Taylor sold 5,500 shares of the firm’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $18.41, for a total transaction of $101,255.00. Following the transaction, the director directly owned 61,573 shares in the company, valued at approximately $1,133,558.93. The trade was a 8.20% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

CeriBell Price Performance

CeriBell stock traded down $0.01 during trading hours on Monday, hitting $18.47. 155,379 shares of the company traded hands, compared to its average volume of 314,499. The firm has a market cap of $700.56 million, a P/E ratio of -11.31 and a beta of 0.85. The company has a quick ratio of 10.01, a current ratio of 10.44 and a debt-to-equity ratio of 0.14. The firm’s 50-day simple moving average is $18.98 and its two-hundred day simple moving average is $19.70. CeriBell, Inc. has a 1-year low of $10.85 and a 1-year high of $24.33.

CeriBell (NASDAQ:CBLL) last released its earnings results on Monday, May 11th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.13). The company had revenue of $26.49 million for the quarter, compared to analyst estimates of $26.09 million. CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. As a group, analysts forecast that CeriBell, Inc. will post -1.69 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CeriBell

Several hedge funds have recently made changes to their positions in CBLL. CenterBook Partners LP boosted its holdings in shares of CeriBell by 448.0% in the third quarter. CenterBook Partners LP now owns 476,554 shares of the company’s stock worth $5,476,000 after buying an additional 389,584 shares during the period. Royce & Associates LP acquired a new position in shares of CeriBell in the fourth quarter worth about $11,695,000. JPMorgan Chase & Co. boosted its holdings in shares of CeriBell by 8.2% in the third quarter. JPMorgan Chase & Co. now owns 411,180 shares of the company’s stock worth $4,724,000 after buying an additional 31,177 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in shares of CeriBell in the first quarter worth about $341,000. Finally, Strs Ohio acquired a new position in shares of CeriBell in the first quarter worth about $27,000.

Analyst Ratings Changes

Several equities analysts have commented on CBLL shares. Canaccord Genuity Group lowered their target price on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, May 12th. Weiss Ratings raised shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 27th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $22.20.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.